Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.77 |
| ▸ | NPC1 | O15118 | 9/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pifexole SCHEMBL2110643 | 0.87 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| Pifexole SCHEMBL29897050 | 0.87 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL9505522 | 0.83 | NPC1 (0.70) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL3432472 | 0.83 | NPC1 (0.64) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL30729303 | 0.83 | NPC1 (0.64) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL3737008 | 0.78 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL31461069 | 0.77 | RAB9A (0.63) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL8050810 | 0.77 | SMN1; SMN2 (1.00) | RAB9ASMN1; SMN2NPC1ACE2TP53 | |
| SCHEMBL23911673 | 0.77 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19 | |
| SCHEMBL5959967 | 0.77 | SMN1; SMN2 (0.85) | RAB9ASMN1; SMN2NPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885SMN1; SMN2 1279/4885NPC1 941/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885SMN1; SMN2 1279/4885NPC1 941/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885SMN1; SMN2 1279/4885NPC1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.